Magle Chemoswed Holding
Magle Chemoswed Holding AB is a Swedish life-science group based in Malmö with operations centered on pharmaceutical chemistry and drug-delivery technologies. Through its subsidiaries, it develops and manufactures APIs, biopolymer-based healthcare products, and diagnostic-related products, while also providing contract development, manufacturing, and laboratory services.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment and manufacturing of APIs and finished pharmaceutical products for clients.
CDMO and manufacturing services focused on dextran and biopolymer-based healthcare products.
Direct sales and distribution of degradable starch microsphere and dextran products.
Analytical development, material characterization, and solid-state analysis services.
Customers
Customers include pharmaceutical companies that need development, scale-up, and manufacturing support for APIs and finished dosage forms. The group also serves medical and diagnostics customers buying proprietary DSM, dextran, and biopolymer-based products, as well as clients needing analytical and material-characterization expertise. Its offering is designed for customers that want regulated, integrated support from early development through commercial supply.
Buy API development, formulation, manufacturing, packaging, and logistics support for drug programs.
Buy trial-ready pharmaceutical products and related manufacturing services for study use.
Buy DSM, dextran, and biopolymer-based products for medical applications.
Buy contract laboratory, material characterization, and process-development services.
Strategy
The group’s strategy is built around integrated pharmaceutical development and manufacturing, combining internal R&D with regulated production capabilities. It also emphasizes proprietary DSM and dextran technologies, using direct sales, distributors, and licensing to extend the reach of its own products while keeping contract manufacturing as a recurring base. The business is focused on allocating resources toward the programs and product lines with the clearest commercial and clinical potential.
Own products can create differentiated demand and licensing value beyond pure contract manufacturing.
End-to-end development and manufacturing capabilities support customer retention and switching costs.
Partners can broaden market reach while reducing the capital burden of commercialization.
Geography
The group is headquartered in Malmö, Sweden, with core operations also in Berlin, Germany and Køge, Denmark. Reported revenue is split between Sweden, Europe excluding Sweden, and other territories, showing a business that sells both within Europe and internationally. Its manufacturing and development footprint is therefore important to regulatory access, customer proximity, and supply-chain execution.
Risks
The business depends on successful development, regulatory compliance, and customer adoption of specialized pharmaceutical and biopolymer products. It also faces execution risk from integrating acquired businesses and from the technical and quality requirements of regulated manufacturing, where delays or failures can affect revenue and asset values. Like other pharma CDMOs, it is exposed to customer concentration, product-development uncertainty, and valuation risk in acquired intangibles and inventory.
- Regulatory and quality complianceImpact: HighLikelihood: Low
The company manufactures APIs and finished products for clinical and commercial use under licenses and approvals.
Exposure: Production and release of regulated pharmaceutical products
- Development and commercialization riskImpact: HighLikelihood: Low
DSM, dextran, and other proprietary programs depend on successful technical and clinical progress.
Exposure: Internal product pipeline and licensing value
- Integration and acquisition riskImpact: HighLikelihood: Low
The group has a portfolio of acquired businesses and assets that must be integrated operationally and financially.
Exposure - Customer and project concentrationImpact: Medium
CDMO revenue can depend on a limited number of projects, programs, or distributors at any time.
Exposure: Third-party development and product sales
- Geographic and currency exposureImpact: Medium
Operations and sales span Sweden, Germany, Denmark, and other territories.
Exposure: Cross-border revenue and costs
Accounting
Judgemental itemsProduct sales, services, and royalties may be recognized at different points in time and under different contract terms.
Impact: Affects quarterly revenue mix and margin comparability
Acquired businesses and technologies create judgment around recoverability and useful lives.
Impact: Can materially affect earnings and equity
Acquisition accounting changes the carrying values of intangibles and tangible assets.
Impact: Influences depreciation, amortization, and book value
Intercompany sales and balances must be removed across subsidiaries.
Impact: Affects reported group revenue and expenses
Similar listed companies
Publicly listed companies with a comparable business focus.
Bactiguard Holding
BACTI-B · Health Care
Bactiguard Holding AB is a global MedTech company based in Stockholm, Sweden, specializing in the development of biocompatible technology to prevent infections associated with medical devices.
Humble Group
HUMBLE · Consumer Staples
Humble Group is a global fast-moving consumer goods (FMCG) conglomerate that focuses on innovative, healthier, and sustainable consumer products.
Trelleborg
TREL-B · Industrials
Trelleborg Group is a global leader in engineered polymer solutions, with a strong presence in industries such as aerospace, automotive, and healthcare.
Boule Diagnostics
BOUL · Health Care
Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics.
Axfood
AXFO · Consumer Staples
Axfood is a prominent player in the Swedish food retail market, operating a diverse range of grocery store concepts including Willys, Hemköp, and City Gross.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Last updated: 24/09/2026